COPYRIGHT © DIGITAL JOURNAL INC. Sitemaps: XML / News. Digital Journal is not responsible for the content of external sites. Read more about our external linking
Las Vega (Nevada), United States //— “Wet Age-Related Macular Degeneration (Wet AMD) Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Wet Age-Related Macular Degeneration Market.
The Wet AMD Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
As per DelveInsight’s assessment, globally, about 70+ key pharma and biotech companies are working on 80+ pipeline drugs in the Wet Age-Related Macular Degeneration therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
Wet Age-Related Macular Degeneration (Wet AMD) Pipeline Analysis
The report provides insights into:
– The report provides detailed insights about emerging therapies for the treatment of Wet AMD and the aggregate therapies developed by major pharma companies.
– It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Wet AMD Treatment.
– It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
– The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
– It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Wet AMD market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Delveinsight’s Report Covers Emerging Products Under Different Phases of Clinical Development Like –
– Late-stage products (Phase III)
– Mid-stage products (Phase II)
– Early-stage products (Phase I/II and Phase I)
– Pre-clinical and Discovery stage candidates
– Discontinued & Inactive candidates
Route of Administration
Wet Age-Related Macular Degeneration (Wet-AMD) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as –
– Inhalation
– Inhalation/Intravenous/Oral
– Intranasal
– Intravenous
– Intravenous/ Subcutaneous
– Oral
– Oral/intranasal/subcutaneous
– Parenteral
– Subcutaneous
Molecule Type
Products have been categorized under various Molecule types, such as
– Antibody
– Antisense oligonucleotides
– Immunotherapy
– Monoclonal antibody
– Peptides
– Protein
– Recombinant protein
– Small molecule
– Stem Cell
– Vaccine
Mechanism of Action (MOA) of the Emerging Pipeline Therapies
– Angiogenesis inhibitor
– Gene transference
– Chemokine CCL11 inhibitor
– Transforming growth factor beta2 expression inhibitors
– Fibroblast growth factor inhibitor
– Vascular endothelial growth factor A inhibitor
– Vascular endothelial growth factors inhibitors
– Complement C5a inhibitor
Wet Age-Related Macular Degeneration (Wet AMD) Therapeutics Landscape
There are approx. 70+ key companies developing therapies for Wet Age-Related Macular Degeneration (Wet-AMD). Currently, Luye Pharma is leading the therapeutics market with its Wet Age-Related Macular Degeneration (Wet-AMD) drug candidates in the most advanced stage of clinical development.
Some of the key companies in the Wet Age-Related Macular Degeneration (Wet AMD) Therapeutics Market include:
Opthea Limited, Outlook Therapeutics, Kodiak Sciences, Regenxbio, Dobecure, Gemini Therapeutics, Huabo Biopharm, Isarna Therapeutics, IVERIC bio (formerly Ophthotech Corporation), Tasly Pharmaceutical Group, Ribomic, Innovent Biologics, GrayBug Vision, Curacle, Quark Pharmaceuticals, Bio-Thera Solutions, AngioLab Inc, Alkahest, Tyrogenex, Iconic Therapeutics, AiViva BioPharma, Boehringer Ingelheim, RemeGen, PanOptica, Clearside Biomedical, Feramda, AsclepiX Therapeutics, Unity Biotechnology, Kyowa Kirin, Ocular Therapeutix, Janssen Research & Development, EyePoint Pharmaceuticals, Shanghai Biomabs Pharmaceutical, Aerie Pharmaceuticals, Ashvattha Therapeutics, Roche, Noveome, Sunshine Guojian Pharmaceutical (Shanghai), Adverum Biotechnologies, Zhaoke Ophthalmology, 4D Molecular Therapeutics, Abpro Corporation, Novelty Nobility, Kala Pharmaceuticals, Kala Pharmaceuticals, Surrozen, Samjin Pharm, and many others.
Wet Age-Related Macular Degeneration (Wet AMD) Therapies covered in the report include:
– LY09004: Luye Pharma
– KSI-301: Kodiak Sciences
– GEM-103: Gemini Therapeutics
– Zimura: Iveric Bio
– RC 28 E: RemeGen
– BI 836880: Boehringer Ingelheim
– AAVCAGsCD59: Janssen Research and Development
– AXT107: Asclepix Therapeutics
– Faricimab: Roche
And many more
Explore More About the Emerging Drugs and Key Companies: Wet Age-Related Macular Degeneration Pipeline Development Activities
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Wet Age-Related Macular Degeneration Current Treatment Patterns
4. Wet Age-Related Macular Degeneration – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Wet Age-Related Macular Degeneration Late-Stage Products (Phase-III)
7. Wet Age-Related Macular Degeneration Mid-Stage Products (Phase-II)
8. Wet Age-Related Macular Degeneration Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Wet Age-Related Macular Degeneration Discontinued Products
13. Wet Age-Related Macular Degeneration Product Profiles
14. Key Companies in the Wet Age-Related Macular Degeneration Market
15. Key Products in the Wet Age-Related Macular Degeneration Therapeutics Segment
16. Dormant and Discontinued Products
17. Wet Age-Related Macular Degeneration Unmet Needs
18. Wet Age-Related Macular Degeneration Future Perspectives
19. Wet Age-Related Macular Degeneration Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Get a Detailed Assessment into the Ongoing Clinical and Regulatory Development Activities, at: Wet Age-Related Macular Degeneration Therapeutic Outlook
Contact Info:
Shruti Thakur
Manager (Marketing and Branding)
Email: info@delveinsight.com
https://www.delveinsight.com/
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.